(RTTNews) - Novo Nordisk (NVO) said that it has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the US Food and Drug Administration. In ...

Despite patent expirations on both fast-acting insulin taken at mealtime, and long-acting insulin, which controls blood glucose levels for 24 hours, the market remains under the control of Novo ...

PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp ® (insulin aspart injection) 100 Units/mL, a fast ...

Novo Nordisk may lose some ground on fast-acting insulin, but should maintain sales of long-acting insulin if patients strongly prefer the convenience of weekly injections. 10 stocks we like ...

The list price of a vial of rapid-acting NovoLog, one of the most widely used insulin products, will fall to $72, from $289. The new price was still about twice what it was when NovoLog was ...

For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval. The drugmaker's Fiasp won its U.S.

The FDA approved Novo Nordisk's Fiasp, an insulin aspart injection to be used as a mealtime insulin option for children with diabetes, the company announced Jan. 6.

Hard on the heels of Eli Lilly's decision to abandon insulin peglispro, rival Novo Nordisk is moving ahead with its faster-acting insulin aspart, filing for FDA approval of the mealtime insulin ...

The FINANCIAL — Novo Nordisk on March 29 announced that the company has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the US Food and ...

Nov 8 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced ...

According to Novo Nordisk, Levemir FlexPen will be discontinued on April 1, 2024, with supply disruptions expected by mid-January 2024. Levemir vials will be discontinued on December 31, 2024.

Novo Nordisk NVO announced that it submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. This mealtime insulin is being.